Skip to main content

Can mRNA Vaccine Momentum Propel Tumor Immunotherapies?

A guide to mRNA-based cancer vaccines and where they’re headed next

Written byAparna Nathan, PhD
| 4 min read
istock image 800x560
Register for free to listen to this article
Listen with Speechify
0:00
4:00

mRNA vaccines made headlines this year as they protected millions of people against COVID-19. But mRNA vaccines have been a decades-long subject of investigation for many diseases, including cancer.

“mRNA vaccines are a great candidate for cancer therapy,” said John Cooke, medical director of the RNA Therapeutics Program at Houston Methodist. “They are a biological software that can be rapidly generated, modified, and delivered.”

Therapeutics specifically targeting tumors are notoriously tricky to design, and mRNA vaccines are no exception. But years of research has finally pushed a handful of mRNA-based cancer vaccines into clinical trials. The rapid development and success of the mRNA vaccine for COVID-19 has also given these efforts a boost. In the past year, there has been increased interest in these mRNA-based immunotherapies. Scott Kopetz, a physician-scientist at the University of Texas MD Anderson Cancer Center, started working with BioNTech on a cancer mRNA vaccine trial before ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • Aparna Nathan, PhD

    Aparna is a freelance science writer with a PhD in bioinformatics and genomics from Harvard University. She uses her multidisciplinary training to find both the cutting-edge science and the human stories in everything from genetic testing to space expeditions. She was a 2021 AAAS Mass Media Fellow at the Philadelphia Inquirer. Her writing has also appeared in Popular Science, PBS NOVA, and The Open Notebook.

    View Full Profile

Related Topics

Related articles background image
The Scientist October Digest cover
October 2026

Antarctica’s Blood Falls Teems With Mysterious Microbial Life

Miles away from the closest ocean, marine microbes thrive in the red ice and mud around Blood Falls, offering clues to microbial adaptation and past climate events.

View this Issue
Find better biologics faster with Stunner and the AI Developability Workcell

Find better biologics faster with Stunner and the AI Developability Workcell

Unchained Labs
An image of microcentrifuge tubes arranged within colorful laboratory racks.

Choose clarity. Choose speed. Choose MyMass™

Refeyn
Characterizing LNP Heterogeneity With Super-Resolution Imaging

Characterizing LNP Heterogeneity With Super-Resolution Imaging

Oni
Conceptual multicolored image of DNA helices.

Exploring the Most Impactful CRISPR Stories

Promega

Products

A monoclonal antibody surrounded by immune cells and red blood cells

CellRaft AIR: Find the Right Antibody-Producing Cells Faster

Cell Microsystems
Maxwell® Rapid ccfDNA Kit

Maxwell® Rapid ccfDNA Kit: Automated Purification of ccfDNA in Under 30 Minutes

Promega
Leica Biosystems, Tempus, and Paige logos side by side, marking the addition of Paige digital pathology AI tools to the Aperio AI Store.

Oncology Researchers Gain AI Cancer Tools in One Platform

Beckman Coulter Life Sciences Logo

Beckman Coulter Life Sciences Launches Vi-CELL BLU 2.0 Software to Advance Data Integrity and GMP Readiness in Cell Analysis